A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Recruiting

Phase 3

VAX-31 & Seasonal Influenza VaccineA Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Sponsor:

Vaxcyte, Inc.

Code:

NCT07365826

Conditions

Pneumococcal Vaccines

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Interventions

31-valent pneumococcal conjugate vaccine

Seasonal Influenza Vaccine (SIV) (Flublok)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-28. This information was provided to ClinicalTrials.gov by Vaxcyte, Inc. on 2026-01-26.